ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)
Description
Brief Summary
The objective of this trial is to confirm that the modifications to tissue processing, valve
sterilization and packaging do not raise any new questions of safety and effectiveness in
subjects who require replacement of their native or prosthetic aortic or mitral valve.
Detailed Description
Multicenter, prospective, single arm trial - Up to seven hundred (700) aortic valve
replacement (AVR) subjects and up to three hundred twenty-five (325) mitral valve
replacement (MVR) subjects at up to forty (40) clinical sites will be enrolled. The trial
will include male and female patients, 18 years or older, requiring replacement for a
diseased, damaged, or malfunctioning native or prosthetic aortic or mitral valve. Patients
will be followed and assessed after implant for up to 5 years.
Phase
N/AInclusion and Exclusion Criteria
- Is 18 years or older
- Provides written informed consent prior to trial procedures
- Agrees to attend all follow-up assessments for up to 5 years and is willing to comply with specified follow-up evaluations at clinical investigational sites that are participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic tests at centers that are under the same IRB or the same healthcare system
- Diagnosed with aortic or mitral valve disease requiring valve replacement based on pre- operative evaluation
- Scheduled to undergo planned aortic or mitral valve replacement with or without concomitant bypass surgery
- Scheduled to undergo planned aortic valve replacement with or without resection and replacement of the ascending aorta from the sinotubular junction and without the need for circulatory arrest for hemi arch or arch replacement
- A subject meeting any of the following criteria shall be excluded:
- Requires emergency surgery
- Requires multiple valve replacement/ repair (with the exception of mitral valve replacement with tricuspid valve repair)
- Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
- Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)
- Requires surgical replacement of the aortic root
- Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the scheduled aortic or mitral valve replacement surgery
- Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mg/dL or end -stage renal disease requiring chronic dialysis at screening visit
- Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery
- Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery
- Has presence of non-cardiac disease limiting life expectancy to less than 12 months
- Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)
- Diagnosed with abnormal calcium metabolism and hyperparathyroidism
- Exhibits left ventricular ejection fraction ≤ 20% as validated by diagnostic procedure prior to planned valve surgery
- Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation
- Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery
- Documented leukopenia (WBC < 3.5x 10³/
Sites
-
California
- University of Southern California, Los Angeles, California, 90033
-
Oklahoma
- Oklahoma Heart Hospital, Oklahoma City, Oklahoma, 73135
-
Kansas
- University of Kansas Medical Center, Kansas City, Kansas, 66160
-
Texas
- Baylor College of Medicine, Houston, Texas, 77030
-
Indiana
- St. Vincent Medical Group, Indianapolis, Indiana, 46290
-
Michigan
- Spectrum Health Hospital, Grand Rapids, Michigan, 49503
-
Georgia
- Emory University Hospital Midtown, Atlanta, Georgia, 30308
Powered by
SC CTSI